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Introduction
Phenotypic sex results from the differentiation of 
internal ducts and external genitalia under the influence of
sex-determining genes and hormones (1,2,3,4,5,6,7,8). In
one of every 4500 births, the genital appearance is abnormal
and it is not possible to decide at first glance  the sex of the
infant. Disorders of sexual development (DSD) are a very
important clinical issue with its different aspects relating to
diagnosis, treatment and sex of rearing. The classification of
ambiguous genitalia in patients is difficult because similar or
identical phenotypes may have several aetiologies
(1,2,3,4,5). 
Physiology of Sex Development  
Sex determination is the result of a series of molecular
events that direct the undifferentiated bipotential gonad to
become either a testis or an ovary. The bipotential gonad
develops from the urogenital ridge. By 6-7 weeks of fetal
life, fetuses of both sexes have two sets of internal ducts:
the Müllerian ducts and the Wolffian ducts. The external
genitalia at 6-7 weeks  gestation appear female and include
a genital tubercle, the genital folds, urethral folds and a 
urogenital opening. During the bipotential stage, many
genes  (WT1, SF1, LHX9, LIM1, PAX2, GATA4, EMX2,
WNT4) are expressed at similarly low levels in XY and XX
gonadal ridges (9,10,11,12,13). However, all are necessary
for normal gonadal development in both sexes, with gene
dosage and relative expression levels playing an important
role in the sexually divergent fate of the gonads. The
steroidogenic factor 1 (SF1), Wingless-type gene (WNT4)
and Wilms tumor suppressor gene 1 (WT1) are expressed in
the urogenital ridge and have a role in the formation of the
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Reviewgonads, kidneys and adrenal cortex. SF1 located on 
chromosome 9p33, is important for the biosynthesis of
adrenal and gonadal steroids and for the development of
the ventral nucleus of the hypothalamus. SF1 is expressed
in the bipotential gonad of both sexes. Expression of SF1
continues in the developing testis, but is repressed in the
ovary. The WT1 gene is located on chromosome 11p13 
and encodes a transcription factor necessary for the 
development of the bipotential gonad and the kidneys.
Wilms tumor suppressor gene activates transcription of
SRY (15,16). The important event in gonadal differentiation
is the commitment of the bipotential gonad to become
either an ovary or a testis. The essential genes affecting
this process are as follows: WT1, SF1,CBX2, SOX9,
fibroblast growth factor 9 (FGF9),  prostaglandin D2 (PGD2),
DAX1, WNT4, forkhead family transcription factor 2
(FOXL2), R-Spondin 1 (RSPO1) and β-catenin. While SOX9,
FGF9 and PGD2 have more testis-promoting activity, DAX1,
WNT4, FOXL2, RSPO1 and  β-catenin are predominantly
ovary-promoting genes (12). SOX9/FGF9 and WNT4/RSPO1
act as antagonistic signals in early gonadal differentiation.
Male Differentiation: The factors involved in testicular
differentiation are given in Figure 1 (14,15,16,17,18,19,20,21).
Male phenotypic development can be viewed as a two-step
process: 1) testis formation from the primitive gonad 
(sexual determination) and 2) internal and external genitalia
differentiation by action of hormones secreted by the fetal
testis (sexual differentiation) (10). 
The first step  involves the interplay of several transcription
factors and signaling cells (14,15,16,17,18,19,20,21). The
DAX1 gene region on Xp21 is necessary for gonadal 
development in both sexes.  A single copy of the DAX1 is
essential for normal testicular cord formation. However,
DAX1 overexpression in an XY fetus impairs testis 
differentiation. Testis determination occurs at about the
sixth week of gestation. SRY gene that is located on the 
Y-chromosome (Yp11.3) initiates sex determination by
downstream regulation of sex-determining factors.
Expression of several genes including WT1,CBX2(M33),
SF1, GATA4/FOG2 is critical to SRY activation. The SRY
gene encodes a unique transcription factor that activates a 
testis-forming pathway (12,18,19). After expression of SRY,
SOX9 (SRY-related HMG box gene) expression is 
upregulated in the developing testis (20). The SOX9 gene,
located  on 7q24.3-25.1, is essential for early testis
development.  SOX9 up-regulates PGD2 and FGF9 genes.
FGF9 and  PGD2 maintain  SOX9 expression, forming a 
positive feed-forward loop in XY gonads (21). The balance
between  FGF9 and  WNT4/RSPO1/β-catenin signals is 
shifted in favor of FGF9, establishing the male pathway. On
the other hand, DMRT1,  ATRX and  DHH and several 
autosomal genes are also involved in testes determination (12). 
The second step in male sex differentiation is a more
straightforward process. The production of anti-Müllerian
hormone (AMH) by Sertoli cells and androgens by 
Leydig cells in a critical concentration-dependent and 
time-dependent manner induces male sexual differentiation
by means of a hormone–dependent process. AMH acts on
its receptor in the Müllerian ducts to cause their regression.
Testosterone (T) acts on the androgen receptor (AR) in the
Wolffian ducts to induce the formation of epidydimis, 
deferent ducts and seminal vesicles. The Leydig cells also
produce insulin-like factor 3 (INSL3, relaxin-like factor),
which causes the testes to descend to the scrotum. T is
further reduced to dihydrotestosterone (DHT), which acts
on the androgen receptor of the prostate and external 
genitalia to cause its masculinization. Binding of T or DHT to
AR is necessary for androgen effect. Various coregulators
interact probably for transcriptional activity of AR. By 
contrast, coregulators such as corepressors repress 
transcriptions (22,23).
Female Differentiation: The factors involved in ovarian
differentiation are given in Figure 2 (24,25,26,27). In the
absence of SRY, the support cell precursors differentiate as
granulosa cells, thus initiating the ovarian pathway. DAX1 is
necessary for both testicular and ovarian development, with
a need for precise gene expression dosage. Overexpression in
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Figure 1. Factors involved in testes differentation
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Figure 2. Factors involved in ovarian differentation
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WNT4/RSPO1/β-catenin pathway blocks FGF9 and promotes
the ovarian fate (24). In XX gonads, WNT4 dominates and
results in an induction of β-catenin and silencing of FGF9 and
SOX9. WNT4-signaling pathway plays a major role in ovarian
development and maintenance, regulation of Müllerian ducts
formation and ovarian steroidogenesis (26,27,28). WNT4 has
been shown to play a critical role  in the development of the
reproductive system and  also in the formation of the 
kidneys, adrenals, pituitary gland, and mammary tissues.
Absence of WNT4 leads to testis-like development within
the ovary. Conversely, overexpression of WNT4 in the male
leads to female sex reversal. RSPO1 is another gene 
essential in sex determination responsible for the protein
RSPO1, which plays an important role in suppression of the
SOX9 gene (27,28). Loss of function mutations in the human
RSPO1 gene in mice results in the formation of ovotestes in
the XX fetus (28). WNT4, RSPO1 and  β-catenin seem to
have both pro-ovarian and anti-testicular activities from early
embryonic life, while FOXL2 may also have similar actions
postnatally.* FOXL2 is expressed early within the genital ridge
of the fetal, postnatal and adult ovary and eyelids. FOXL2 is
involved in granulosa cell differentiation, follicle development
and maintenance during fertile life (29). Müllerian ducts give
rise to the fallopian tubes, uterus and the upper two-third of
the vagina. In the female, the genital tubercle becomes the 
clitoris, the labio-scrotal folds become the labia majora, and
the urethral folds become the labia minora. 
Nomenclature and Definitions  
Formerly, intersex disorders were subdivided into three
main groups as: associated with gonadal dysgenesis, 
associated with undervirilization of 46,XY individuals, 
and conditions associated with prenatal virilization of 46,XX
subjects. The nomenclature used to describe atypical 
sexual differentiation has since changed (2,3,4,5). Instead of
using the confusing and/or controversial terms such as 
"intersex," "hermaphroditism" and "sex reversal", the 
consensus statement recommended a new taxonomy based
on the umbrella term, “DSD” (3). This broad category
includes common entities such as Turner syndrome and
Klinefelter syndrome as well as rare disorders such as 
cloacal exstrophy and aphallia. Many DSDs are associated
with ambiguous genitalia,  however, a few may present with
delayed puberty or primary amenorrhea. The Lawson Wilkins
Pediatric Endocrine Society (LWPES) and the European
Society for Paediatric Endocrinology (ESPE) consensus 
group proposed the classification of DSDs into: 1) Sex 
chromosome DSDs  (45,X Turner and variants, 47,XXY
Klinefelter and variants, 45X/46XY mixed gonadal disgenesis
(MGD) and chromosomal ovotesticular DSD “46XX/46XY
chimeric type  or mosaic type”); 2) 46,XY DSDs (disorders of
testicular development or disorders in androgen 
synthesis/action); and 3)  46,XX DSDs (disorders of ovarian
development or fetal androgen excess) (Table 1). Additional 
categorization based on sex chromosome complement was
recommended but not clearly defined  (30,31). It is recognized
that some conditions do not fit exactly into one specific 
diagnostic category or may be placed in more than one category
(5). The DSD nomenclature has recently divided "ovotesticular
DSD" (formerly true hermaphroditism) into 46,XY ovotesticular
DSD, 46,XX ovotesticular DSD, and chromosomal ovotesticular
DSD (46,XX/46,XY” chimerism or 45,X/46,XY” mosaic type). 
1) Sex chromosome DSDs (45,X Turner and variants,
47,XXY Klinefelter and variants, 45X/46XY MGD, 
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Table 1.  Disorders of sexual development (New DSD nomenclature) (3)
Sex Chromosome DSD 46,XY DSD 46,XX DSD
• 45,X Turner and Variants D Di is so or rd de er rs s   o of f   T Te es st ti ic cu ul la ar r    D Di is so or rd de er rs s   o of f    D Di is so or rd de er rs s   o of f   O Ov va ar ri ia an n F Fe et ta al l      A An nd dr ro og ge en n      E Ex xc ce es ss s
• 47,XXY Klinefelter and Variants D De ev ve el lo op pm me en nt t A An nd dr ro og ge en n D De ev ve el lo op pm me en nt t C CA AH H N No on n   C CA AH H
• 45,X/46XY MGD •Complete Gonadal  S Sy yn nt th he es si is s/ /A Ac ct ti io on n
• Chromosomal Ovotesticular  Dysgenesis
DSD • Partial Gonadal   
Dysgenesis
• Gonadal Regression
• Ovotesticular DSD
• Androgen Synthesis
Defect
• LH-Receptor Defect
• Androgen Insentivity
•5 α-Reductase
Deficiency
• Disorders AMH 
• Timing Defect
• Endocrine Disrupters
• Cloacal Extrophy
• Ovotesticular DSD 
• Testicular DSD (eg.
SRY+, dup SOX9)
• Gonadal
Dysgenesis
• 21-OH Deficiency
• 11-OH Deficiency
• Aromatase
Deficiency
• POR Gene
Defect
• Maternal 
• Luteoma
• Iatrogenic
MGD: mixed gonadal dysgenesis, DSD: disorders of sexual development, AMH: anti-Müllerian hormone, CAH: congenital adrenal hyperplasiachoromosomal ovotesticular DSD (46XX/46XY chimeric type
or mosaic type): This type of DSDs is associated with a
numerical sex chromosome abnormality leading to 
abnormal gonadal development (2,3,5,30,31,32,33,34,
35,36,37). Sex chromosome DSD was formerly termed as
gonadal dysgenesis in most of the patients in this group (5).
If a testis is poorly formed, it is called a dysgenetic testis, and
if an ovary  is poorly formed, it is called a streak gonad. A
patient with a Y chromosome is at high risk of developing a
tumor in a streak or dysgenetic gonad. Klinefelter and Turner
syndromes (TS) are the most frequently encountered  sex
chromosomal abnormalities (34,35,36). More than half of
girls with TS have chromosomal mosaicism. The most 
common genotype of Klinefelter syndrome is XXY, although
variants exist with different numbers of X chromosome. In
patients with 45X/46XY MGD, clinical manifestations are
highly variable, ranging from partial virilization and ambiguous
genitalia at birth to  a completely male or female phenotype.
The most common feature of MGD is asymmetric 
development of the testes, often with a dysgenetic testis on
one side and a streak gonad on the other. Asymmetrical
external and internal genitalia may also be present. The 
presence of 45,X cell lines is frequently associated with Y
chromosome rearrangements (commonly dicentric and ring
Y chromosomes), which may also have an impact on the 
phenotype.  Chromosomal ovotesticular DSD (chimeric type
or mosaic type) is associated with ovarian and testicular 
tissues found in either the same or opposite gonad just as in
46,XX and 46,XY ovotesticular DSD. The genital duct 
develops  according to the ipsilateral gonad. 
2) 46,XY disorders of sex development (46,XY DSD):
The term “male pseudohermaphrodite” was used to
describe the patients with incompletely masculinized 
external genitalia possessing an XY chromosome.** 46,XY
DSD can result either from disorders of testicular 
development or disorders in androgen synthesis/androgen
action (6). These patients are characterized by ambiguous
or female external genitalia, caused by incomplete 
intrauterine masculinization. Male gonad(s) are palpable in
the majority of 46,XY DSD patients. Abnormalities in 
the expression of genes involved in the cascade of testis
determination can cause anomalies of gonadal 
development and consequently, 46,XY DSD (complete or
partial forms of gonadal dysgenesis with or without 
syndromic phenotype, ovotesticular DSD, testicular 
regression syndrome). 
Failure of testis determination results in the development
of the female phenotype, while genetic alterations resulting
in partial testicular development can give rise to a wide
spectrum of incomplete masculinization. 46,XY partial
gonadal dysgenesis,  characterized by partial testicular 
differentiation and  ambiguous genitalia, is usually observed
in the newborn period. Mutation in WT1 gene results in
Denys-Drash syndrome (without uterus) or Frasier 
syndrome (with uterus) characterized by 46,XY partial
gonadal dysgenesis and severe renal dysfunction with or
without Wilms tumor (16). Complete  gonadal dysgenesis in
46,XY individuals (Swyer syndrome) is characterized by a
female phenotype with full development of unambiguous
female genitalia, normally developed Müllerian structures,
and streak gonads. These streak gonads are removed due
to their association with gonadoblastoma. In general, these
patients present because of delayed puberty. In agonadism
(vanishing testes syndrome, testicular regression) boys
present with normal male genitalia, indicating that they
must have had testicular function in the fetal period, and
bilateral anorchia.
The defects in peptide hormones and their receptors as
well as the timing of hormonal exposure are also critical to
appropriate male development. Leydig cell aplasia/hypoplasia,
due to abnormalities in hCG/LH receptor, and T 
biosynthesis defects (STAR deficiency, P450scc deficiency,
3-β hydroxysteroid dehydrogenase type II deficiency, 
17α-hydroxylase and 17,20-lyase deficiency, isolated 
17,20-lyase deficiency, P450 oxidoreductase ”POR gene”
defect, 17β-hydroxysteroid dehydrogenase III deficiency)
result in androgen synthesis defect. Severely affected
infants for POR gene of both sexes have ambiguous 
genitalia. The males are undervirilized because of defective
17,20-lyase activity of P450c17. Disorders of AMH and
AMH receptors result in persistent Müllerian duct 
syndrome (PMDS).  PMDS is inherited in a sex-limited 
autosomal recessive manner caused by a mutation in the
AMH or AMH-receptor genes. 5α-reductase type 2 
deficiency (38,39,40) and complete/partial forms of 
androgen insensitivity syndromes (CAIS, PAIS) result in 
disorders of androgen action (22,23).
3) 46,XX disorders of sex development (46,XX DSD):
The term female pseudohermaphrodite was used 
to describe the patients with 46,XX karyotype and with
masculinized external genitalia. Currently, these disorders
are described as 46,XX DSD.** 46,XX DSD can result either
from disorders of ovarian development or fetal androgen
excess (6). SRY positivity; WNT4, RSPO1,  β−catenin gene
defects; and duplication of SOX9 gene lead to testis-like 
formation within the ovary (streak gonad, dysgenetic testis
or ovotestis) in the 46,XX patients. A single copy of the
WNT4 gene in females causes Müllerian abnormalities,
renal abnormalies (e.g. renal agenesis), and androgen
excess. Their phenotype resembles that of patients with
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With absence of both copies of this gene, females show
male sex and SERKAL syndrome (female to male sex 
reversal; renal, adrenal and lung dysgenesis) (26). RSPO1 is
essential in sex determination and skin differentiation.
RSPO1 gene mutations lead to XX sex reversal, 
palmoplantar hyperkeratosis and predisposition to 
squamous cell carcinoma of the skin (27,28). FOXL2
mutations result in a variety of phenotypes, from adult 
ovarian failure to development of streak gonads (29).
Mutations in FOXL2 are responsible for blepharophimosis-
ptosis-epicanthus inversus syndrome (BPES) and can be 
associated with premature ovarian failure. Ovarian 
dysgenesis coexisting with sensorineural deafness is 
diagnosed as Perrault syndrome. In ovotesticular DSDs, the
most common karyotype is 46,XX followed by 46,XX/46,XY
chimerism or mosaicism, and 46,XY. Most 46,XX 
ovotesticular DSDs are SRY-negative, and the genes
responsible have not yet been identified. A mutated 
downstream gene in the sex determination cascade is 
likely to allow for testicular determination. 46,XX testicular
DSD is distinct from XX ovotesticular DSD and is 
associated with male habitus, small testes, azoospermia
and no evidence of uterus or ovaries.
Virilized females with two ovaries, XX karyotype 
and ambiguous genitalia  are usually exposed to external
genitalia androgens of fetal origin or to androgens of 
maternal origin. The majority of virilized 46,XX infants will
have congenital adrenal hyperplasia (CAH) (most 
commonly 21α-hydroxylase and 11β- hydroxylase or rarely
3β-hydroxysteroid dehydrogenase deficiencies). Apparent
combined P450c17 and P450c21 deficiency is a rare 
variant of CAH.  Mutations of POR gene cause disordered
steroidogenesis with prenatal virilization without worsening
of postnatal virilization in female fetuses (41,42).
Cytochrome POR is a protein that transfers electrons from
NADPH to all microsomal cytochrome P450 enzymes and
three steroidogenic enzymes, namely, P450c17
(17α-hydroxylase/17,20 lyase), P450c21 (21-hydroxylase),
and P450aro (aromatase). Severely affected female 
infants for POR gene are virilized because of defective 
aromatase activity and because of the diversion of 
17-hydroxyprogesterone (17OHP) to DHT via the “backdoor
pathway” to androgens that bypass dihydroepiandrosterone
(DHEA), androstenedione (A) and T (42). Severely affected
infants also have the Antley-Bixler skeletal malformation
syndrome (ABS) characterized by craniosynostosis and
radio-humeral or radio-ulnar synostosis. Rarer causes of
fetal androgen excess in XX infants are maternal androgen
ingestion, maternal virilizing disease, fetoplacental 
aromatase deficiency, sulfatase deficiency,  virilizing 
luteoma of pregnancy, glucocorticoid receptor mutation. 
Aromatase deficiency is rare in humans (43). Aromatase
is the enzyme that catalyzes conversion of androgens into
estrogens, and if aromatase is nonfunctional because of an
inactivating mutation, estrogen can not be synthesized. If
the fetus lacks aromatase activity, DHEA produced by the
fetal adrenal glands cannot be converted to estrogen by the
placenta, and is converted to T peripherally. This  results in
virilization of both fetus and mother. 
Cystic ovaries and delayed bone maturation can occur
during childhood and adolescence in these girls. They may
present at pubertal ages with primary amenorrhea, failure
of breast development except in partial cases, virilization,
and hypergonadotrophic hypogonadism. 
Sulfotransferase deficiency is a monogenic cause of
hyperandrogenism. DHEA sulfotransferase, known as
SULT2A1, converts the androgen precursor DHEA to its
inactive sulfate ester, DHEAS, thereby preventing the 
conversion of DHEA to an active androgen. If this pathway
is blocked, more DHEA will be converted to androstenedione
and hyperandrogenism may occur (44). 
Investigation of DSD Patients 
Optimal care of patients with DSD requires a 
multidisciplinary team and begins in the newborn period. A
family history, prenatal history, a general physical 
examination with attention to any associated dysmorphic 
features, and an assessment of the genital anatomy are the
first steps towards a correct diagnosis. The diagnostic 
evaluation of DSD includes hormone measurements, 
imaging, cytogenetic and molecular studies and in some
cases endoscopic, laparoscopic and gonadal biopsy
(6,7,8,45,46,50,51,52,53,54,55). The genetic evaluation
includes karyotype, FISH and, more recently, specific 
molecular studies to screen the presence of mutations or
gene dosage imbalance (AR, SRY, SF1, WT1, CYP21, SOX9,
DAX-1, 17β hydroxysteroid dehydrogenase, 5α-reductase-2,
and others). However, current molecular diagnosis is limited
by cost, accessibility, and quality control. Ultrasonography
shows the presence or absence of Müllerian/Wolfian 
structures and can locate the gonads and their  echo texture.
Ultrasonography also can identify associated malformations
such as renal abnormalities. 
Common findings suggesting DSD are male appearance
with associated abnormalities of genitalia including severe
hypospadias with bifid scrotum, undescended testis/testes
with hypospadias, bilateral non-palpable testes, and
micropenis with chordee (47,48) or female appearance 
with associated abnormalities of genitalia including
enlarged clitoris, posterior labial fusion, and an 
inguinal/labial mass (49). An initial assessment, based on
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uterus, will provide a provisional clinical diagnosis (45). This
information combined with karyotype, will provide the basis
for more focussed further investigation. Figures 3a and 3b
illustrate chromosomal and gonadal characteristics of
DSDs. If no gonads are palpable, all options  are possible.
Of these, 46,XX DSD (with 2 ovaries) is the most 
commonly seen, followed by MGD.  The presence of a
uterus and absence of palpable gonads in a virilized female
primarily suggest a clinical diagnosis of 21-hydroxylase
deficiency. If one gonad is palpable, 46,XX DSD and 
complete gonadal dysgenesis are ruled out because ovaries
and streak gonads do not descend. MGD, ovotesticular, and
46,XY DSD remain as diagnostic possibilities. If two gonads
are palpable, 46,XY DSD and  ovotesticular DSD are the
most likely diagnoses. Symmetrical external genitalia, with
or without palpable gonads, and an absent uterus suggest
an undervirilized XY male. The presence of a uterus and 
asymmetric external genitalia and palpable gonad(s) 
suggest gonadal dysgenesis with Y and ovotesticular DSD.
A gonadal biopsy is required to classify the type of gonadal
dysgenesis and ovotesticular DSD, to assess gonadal 
chromosomal mosaicism and to detect the presence of a
gonadal tumor. 
Hormone measurements should  be interpreted in 
relation to specific assay characteristics and also 
considering  normal values for gestational and chronological
age. In some cases serial measurements may be needed.
The results of decision making algorithms are available to
guide further investigation. These include hCG and ACTH
stimulation tests to assess testicular and adrenal steroid
biosynthesis. The endocrine evaluation of patients 
with 46,XY DSDs and sex chromosome DSDs include
assessment of testicular function by basal measurement of
LH, FSH, inhibin B, T, DHT, AMH, A, and  DHEAS. In patients
with T synthesis defects, neonatal and post pubertal 
diagnosis is made based on  basal steroid levels. The 
stimulation of T production by hCG is used to pinpoint 
abnormalities in T biosynthesis and to detect functioning 
testicular tissue. Testosterone, DHT, A should be measured
at baseline and 72 hours after hCG stimulation. The T 
increment should be at least threefold (56). A failure to
respond to hCG in combination with elevated LH/FSH
levels and low/undetectable value of AMH is consistent
with anorchia or gonadal dysgenesis. Androgen 
insensitivity should be considered in individuals with a
46,XY karyotype and with normal T biosynthesis. The 
diagnosis of androgen insensitivity is difficult in absence of
a defined androgen receptor mutation. Patients with 
5α-reductase deficiency have normal T levels, low or 
normal DHT levels and a high T/DHT ratio after hCG 
stimulation test. The diagnosis of 17βHSD deficiency is
made when a 10-15-fold elevation is observed in the ratio of
A/T. Minimum A/T ratio in a cohort of 24 individuals with a
confirmed mutation was 0.7 (57). Inhibin B and AMH are
useful markers for the presence of Sertoli cells and their
assessment could help in the diagnosis of testis 
determination disorders. In boys with bilateral 
cryptorchidism, serum AMH and inhibin B correlate with
the presence of testicular tissue and undetectable 
values are highly suggestive of absence of testicular tissue
(58). In XY patients, AMH was found low when the intersex
condition was caused by abnormal testicular determination
(including complete and partial gonadal dysgenesis) but
was normal or elevated in patients with impaired 
T secretion, whereas serum T was low in both groups.
AMH was also elevated during the first year of life and at
puberty in intersex states caused by androgen insensitivity.
In 46,XX patients with ambiguous genitalia, a serum AMH
level  higher than 75 pmol/L is indicative of the presence of
testicular tissue and correlates with the mass of functional
testicular parenchyma. In conclusion, serum AMH 
determination is a powerful means  to assess Sertoli cell
function in children with intersex , and helps to distinguish
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OVARY-OVARY
TESTIS-TESTIS
OVOTESTIS
STREAK-TESTIS
46, XX DSD
(Fetal Androgen Excess)
46, XY DSD
(Disorder Androgen Synthesis/Action)
46,XX or 46,XY or
Chromosomal
Ovotesticular DSD
45,X/46,XY
Mixed Gonadal
Dysgenesis
46,XX
Agonadism (Testicular
Regression)
46,XY
Complete Gonadal Dysgenesis
46,XX
Complete Gonadal Dysgenesis
46,XX
46,XX Testicular DSD
Testis Testis
Streak Streak
NO GONADAL
TISSUE 
Figure 3a. Gonadal and chromosomal characteristics of DSD
DSD: disorders of sexual development
Figure 3b. Gonadal and chromosomal characteristics of DSD
DSD: disorders of sexual developmentbetween defects of  abnormal testicular determination and
of isolated impairment of T secretion or action. 
The diagnosis of 21-hydroxylase deficiency in 46,XX
DSDs with two ovaries relies on the detection of elevated
17-OHP levels either as a basal measurement or after 
a short ACTH stimulation test. High concentration of 
11-deoxycortisol and deoxycortisol (DOC) with low levels of
plasma renin activity (PRA) will help differentiate  11- from
21-hydroxylase deficiency. 
Supported by good facilities for investigation, clinicians
can follow an algorithm that in many cases will lead to an
aetiological diagnosis, but with the spectrum of findings
and diagnosis, no single evaluation protocol can be 
recommended in all circumstances (59,60). 
Chromosomal characteristics, gonadal histology and
presence or absence uterus are taken into consideration in
the classification of DSDs. In our department, we use the
diagnostic algorithm prepared in accordance with the new
classification for 46,XY DSD and for 46,XX DSD, as given  in
Figures 4 and 5. 
Management
The psychological and social implications of 
gender assignment and those relating to treatment are very
important and require a multidisciplinary approach with the
inclusion of geneticists, neonatologists, endocrinologists,
gynaecologists, psychiatrists, surgeon and social workers in
the team. The members of such a team should have a 
special interest in DSD and  possess sufficient experience
with this group of patients. The current intense debate on
the management of patients with intersexuality and related
conditions focuses on four major issues, namely, 
aetiological diagnosis, assignment of gender, indications for
and timing of genital surgery, and disclosure of medical
information to the patient (61,62,63,64,65,66,67,68,
69,70,71,72,73). Gender identity is a multifactorial process
involving both prenatal and postnatal variables.
Psychosexual development is influenced by multiple 
factors such as exposure to androgens, sex chromosome
genes, social circumstances and family dynamics.
Outcomes can be influenced by timing, dose and type of
androgen exposure, receptor availability, and modification
by the social environment. Pre- and postnatal hormonal 
conditions, sex rearing, timing of sex reassignment and 
corrective surgery appear to be important components for
the development of gender-role behavior and gender 
identity in DSD patients. Karyotype, gonadal function, 
phenotype, internal genitalia (i.e. presence of uterus),
potential for fertility and sexuality, risk of future malignancy,
and prenatal brain virilization are some of the many factors
which must be taken into account when assessing gender
in a child with DSD. Each patient should be evaluated 
individually by a multidisciplinary approach. Gender 
assignment should be done after completion of the 
diagnostic process, including full clinical, genetic, 
biochemical and psychiatric investigation. The whole 
procedure should be fully explained to the parents and they
should partake in the discussions and decisions. 
The traditional gender assignments for some medical
conditions leading to DSDs are as follows: assignment of
female gender for 46,XX DSD resulting from fetal androgen
exposure, CAIS, and 46,XY complete gonadal dysgenesis;
assignment of male gender for 46,XY cloacal exstrophy;
assignment of male or female gender for PAIS, 5α-
reductase deficiency, ketoreductase deficiency, 46,XY 
partial gonadal dysgenesis, MGD and ovotesticular DSD.
Underlying endocrine disturbances are present in most
cases and usually require long-term medication. The current
recommendation for a girl with CAH is to rear her as a
female and perform a feminizing genitoplasty depending 
on the degree of masculinization. However, male sex
assignment may be mandatory in severely virilized 46,XX
CAH patients in whom the diagnosis was not made in the
early stage.   Recommendations for sex of rearing 
especially in infants with genital ambiguity, testicular 
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Figure 4. Diagnostic algorithm of 46,XY DSD for new classification
DSD: disorders of sexual development
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Figure 5. Diagnostic algorithm of 46,XX DSD for new classification
DSD: disorders of sexual development, CAH: congenital adrenal hyperplasia
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Streak-Streakdifferentiation disorders and Y chromosome continue to be
challenging. Genital masculinization is a poor predictor of
the masculinization of the brain (63). Patients with PAIS, 
5α-reductase and ketoreductase deficiency, partial gonadal
dysgenesis, and MGD may be female or predominantly
female at birth and generally are raised as females, but they
change their social sex to male at puberty. Sex assignment
is more problematic in this group. The decision on sex of
rearing in ovotesticular DSD should be based on gonadal
and internal ductal formation. 
Surgical techniques of 'feminization' and 'masculinization'
and their outcomes have also evolved over time (72,73).
Surgeons should have both pediatric training and expertise in
DSD surgery. Functional outcome should be taken into 
consideration rather than a strictly cosmetic appearance. In 
children assigned a male sex, hypospadias or chordee, if present,
requires early surgical correction. Scrotal testis/testes should be
monitored and, if needed, biopsied, to rule out malignancy. A
streak ovary should be removed. The testis/testes may also
need to be removed if there is any risk of malignancy on clinical
suspicion or biopsy specimens. T replacement may be required
at puberty. The testes in patients with DSD raised as females
should be removed to prevent malignancy in pre-puberty or after
puberty. Feminizing surgery has three main aims: reducing the
size of the enlarged masculinized clitoris, reconstructing the
female labia, and increasing the opening and if possible, the
length of the vagina.  Early surgery should only be considered in
cases of severe virilization (Prader III-V) and should be carried out
in conjunction, when appropriate, with repair of the common 
urogenital sinus. As orgasmic function and erectile sensation
may be disturbed by clitoral surgery, the surgical procedure should
be anatomically based to preserve erectile function and the 
innervation of the clitoris. Consensus conferences recommend
not to perform genital surgery between 12 months and 
adolescence (except for compelling medical indications). Vaginal
dilatation should not be recommended before adolescence. 
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